a Division of Hematology, Department of Medicine , Jichi Medical University , Tochigi , Japan.
b Department of Hematology , Tochigi Cancer Center , Tochigi , Japan.
Leuk Lymphoma. 2019 Mar;60(3):734-741. doi: 10.1080/10428194.2018.1504939. Epub 2018 Sep 6.
Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous disease. To evaluate the clinical relevance of the serum soluble interleukin-2 receptor (sIL-2R) level, we retrospectively analyzed 178 patients aged ≥60 years who were newly diagnosed with DLBCL. We determined the cutoff value of the sIL-2R level to be 1280 U/mL using the area under the receiver operating characteristic curve. The high sIL-2R group exhibited significantly inferior 5-year progression-free survival (PFS) (36.2% vs. 86.1%, p < .001) and 5-year overall survival (OS) (49.7% s. 83.8%, p < .001) than the low sIL-2R group. Multivariate analysis revealed that a high sIL-2R level was a significant prognostic factor for PFS and OS (hazard ratio [HR]: 5.65, p < .001 and HR: 2.99, p = .001, respectively). This study showed that measurement of the sIL-2R level at diagnosis is clinically beneficial for identifying elderly patients with DLBCL who have a poor prognosis.
弥漫性大 B 细胞淋巴瘤（DLBCL）是一种临床异质性疾病。为了评估血清可溶性白细胞介素 2 受体（sIL-2R）水平的临床相关性，我们回顾性分析了 178 例年龄≥60 岁的新诊断为 DLBCL 的患者。我们使用受试者工作特征曲线下的面积确定 sIL-2R 水平的截断值为 1280 U/mL。高 sIL-2R 组的 5 年无进展生存（PFS）（36.2%比 86.1%，p<0.001）和 5 年总生存（OS）（49.7%比 83.8%，p<0.001）明显低于低 sIL-2R 组。多变量分析显示，高 sIL-2R 水平是 PFS 和 OS 的显著预后因素（风险比[HR]：5.65，p<0.001 和 HR：2.99，p=0.001）。这项研究表明，在诊断时测量 sIL-2R 水平有助于识别预后不良的老年 DLBCL 患者。
